(MENAFN- America News Hour)Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. There are many biological therapies that have been approved and being used by various cancer specialists across the globe. While there are many other therapies also which are under the research and development phase and are yet to be available for commercial use.
Biological therapy treatment is treatment process which is performed with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. Most of the biological therapies uses bacteria or vaccines to mimic the body's immune system to act against cancer developing cells. These various types of biological therapies, which are most of the times stated to biological response modifier therapy or immunotherapy, but these types of therapies do not always target cancer cells directly. Further there are other biological therapies like sections of genetic material or antibodies which are commonly known as DNA or RNA, do aim at targeting cancer cells directly. There are some other types of biological therapies that inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as cancer targeted therapies.
Download Sample of This Strategic Report:
The Europe, Middle East and Africa Cancer Biological Therapy market is expected to reach US$ 29,776.3 million by 2023 at a CAGR of 5.0% during the forecast period.
EMEA Cancer Biological Therapy Market is further segmented into type of therapy which include Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Cancer Growth Blockers, Interferons, Interleukins, Gene Therapy, Targeted Drug Delivery, Colony Stimulating Factor, Cancer Vaccines and other therapies. The Monoclonal Antibodies segment includes sub segment namely Naked Monoclonal Antibodies. Interferon segment is further sub segmented into Alpha Interferon, Beta Interferon and Gamma Interferon.
On the basis on end users cancer biological therapy market is segmented into Hospitals & Clinics, Laboratories, Cancer Research Centers and other end users. Hospitals & Clinics accounted for the largest market share of EMEA cancer biological therapy market. Hospitals & Clinics commands maximum share of EMEA cancer biological therapy market in 2015.
On the basis of region, Europe accounted for the largest market share in biological therapy market. While Middle East and Africa region is expected to grow with a steady pace during forecast period.
Key Players:
The leading market players in the Europe, Middle East and Africa Cancer Biological Therapy market include Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, ELI Lilly and Company, EnGeneIC Ltd., EnGeneIC Ltd., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis, Pfizer Inc, Seattle Genetics Inc. and Teva Pharmaceutical Industries Ltd.
Study objectives of Cancer Biological Therapy market:
• To provide insights about factors influencing and affecting the market growth
• To provide historical and forecast revenues of the market segments and sub-segments with respect to regional and country-level markets
• To provide historical and forecast revenue of the market segments based on type of therapy, end users, and its sub-segments.
• To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
Request For Full Report-
Target Audience:
• Medical devices distributors
• Hospitals & Clinics
• Potential investors
• Key executive (CEO and COO) and strategy growth manager
• Pharmaceutical companies
Key Findings:
• Europe accounted for the largest market share of monoclonal antibodies cancer biological therapy market, registering $5,316.8 million in 2015 and expected to reach at $6,844.1 million by 2021
• Targeted Therapy is the fastest growing segment with a CAGR of and 5.7% in EMEA
• Cancer growth blockers is contributing remarkable share towards the market registering $4,990.5 million in 2015
The reports also covers regional analysis:
• Europe
• Western Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest Of Europe
• Middle East
• Gulf Cooperation Council (GCC)
• Qatar
• UAE
• Kuwait
• Bahrain
• Oman
• Saudi Arabia
• Rest of Middle East
• Africa
About Kenneth Research:
Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products'' demand, growth and opportunities for new and existing players.
Contact Us
Kenneth Research
Email:
Phone: +1 313 462 0609
Steven is working as a news editor with America News Hour. He started his career as a freelance news writer in 2012 and has helped people in all aspects of online marketing through the expert industry coverage. In addition to writing content as a freelancer, he is also an expert in business, lifestyle, politics, sports and tech & science news. His articles are now featured on the overwhelming news website and channels such as MarketWatch, Routers etc.
MENAFN08052021004545010068ID1102048348
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.